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Disclaimer 
 
 This document was prepared as an account of work sponsored by an agency of the United States 
Government. Neither the United States Government nor the University of California nor any of their 
employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for 
the accuracy, completeness, or usefulness of any information, apparatus, product, or process 
disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any 
specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, 
does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United 
States Government or the University of California. The views and opinions of authors expressed herein 
do not necessarily state or reflect those of the United States Government or the University of California, 
and shall not be used for advertising or product endorsement purposes. 
 
Comment on “Steady State Solutions to PBPK Models and their Applications to Risk 
Assessment I: Route to Route Extrapolation of Volatile Chemicals,” by Chiu and White 
in Risk Analysis, 26(3), 769-780 
 
Steady-state analyses of generic PBPK models for volatile organic chemical (VOC) exposure 
and risk assessment have been undertaken and applied for nearly two decades now.(1-5)  Chiu and 
White’s paper on this subject adds little new to this earlier work.  Their dismissive claim that 
“Similar analyses have been done for specific chemicals(3,4) and for inhalation(5)” is misleading, 
because some of this earlier work did indeed focus on “generic” PBPK models generally 
applicable to VOC exposure by multiple routes.  In particular, the earliest of these previous 
studies(1,3,4) developed steady-state solutions for generic PBPK models including respiratory and 
1-compartment oral routes of exposure, and further specified how to add injection and dermal 
exposure routes.  Chiu and White included a 2-compartment oral pathway and a lung 
compartment in an otherwise identical generic PBPK model, but did not consider other exposure 
pathways such as dermal uptake.  Each of the earlier studies(1,3,4) first presented a steady-state 
solution to a generic, multiroute PBPK model, and only then applied the generic solution to a 
problem or illustration involving a specific compound—i.e., the same approach used later by 
Chiu and White.  For example, my earlier study(3) included a simple, intuitive expression for 
low-dose metabolized fraction fm* of any applied multiroute dose, allowing route-to-route 
extrapolation regardless of compound in low-dose contexts that typically are of interest in 
environmental VOC risk assessment.  Section 2.2 of Chiu and White’s paper (“Generalization to 
Time-Varying Exposures”) concludes that, under conditions of virtually linear metabolism, 
PBPK system “solutions to steady-state exposures are directly applicable to intermittent 
exposures”—i.e., under such conditions, all steady-state system solutions (or output states) 
become valid when each dynamic input is replaced by its corresponding time-weighted average 
value.  This conclusion, a well known axiom of linear systems theory, was stated explicitly to 
apply to fm* in my earlier study.(3)  A subsequent study(2) addressed how generic steady-state 
PBPK solutions can be modified to estimate transient peak target-tissue concentrations at 
dynamic equilibrium, for dynamic exposure scenarios that involve exposure to a regular (e.g., 
daily) series of brief inputs by multiple pathways—an issue (not addressed by Chiu and White) 
that may be of importance for endpoints that have a cytotoxic mechanism of action. 
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